Hoey Investments Inc. Raises Stake in Johnson & Johnson (NYSE:JNJ)

Hoey Investments Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 18.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,413 shares of the company’s stock after acquiring an additional 380 shares during the period. Hoey Investments Inc.’s holdings in Johnson & Johnson were worth $349,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in JNJ. Norges Bank acquired a new position in Johnson & Johnson during the fourth quarter valued at $4,390,037,000. Raymond James Financial Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $1,339,878,000. Janus Henderson Group PLC boosted its stake in shares of Johnson & Johnson by 228.1% in the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock worth $549,223,000 after buying an additional 2,356,359 shares during the last quarter. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock worth $33,666,460,000 after acquiring an additional 1,772,706 shares during the period. Finally, Franklin Resources Inc. raised its position in Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after acquiring an additional 1,729,281 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on JNJ shares. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $163.63 on Monday. The firm has a 50-day simple moving average of $158.68 and a 200-day simple moving average of $156.07. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $394.32 billion, a price-to-earnings ratio of 24.61, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the company posted $2.29 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.03%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.